These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31870630)

  • 21. Outcomes of Cystic Fibrosis Screening-Positive Infants With Inconclusive Diagnosis at School Age.
    Gonska T; Keenan K; Au J; Dupuis A; Chilvers MA; Burgess C; Bjornson C; Fairservice L; Brusky J; Kherani T; Jober A; Kosteniuk L; Price A; Itterman J; Morgan L; Mateos-Corral D; Hughes D; Donnelly C; Smith MJ; Iqbal S; Arpin J; Reisman J; Hammel J; van Wylick R; Derynck M; Henderson N; Solomon M; Ratjen F
    Pediatrics; 2021 Dec; 148(6):. PubMed ID: 34814176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype.
    Parad RB; Gerard CJ; Zurakowski D; Nichols DP; Pier GB
    Infect Immun; 1999 Sep; 67(9):4744-50. PubMed ID: 10456926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulatory effect of the SLC9A3 gene on susceptibility to infections and pulmonary function in children with cystic fibrosis.
    Dorfman R; Taylor C; Lin F; Sun L; Sandford A; Paré P; Berthiaume Y; Corey M; Durie P; Zielenski J;
    Pediatr Pulmonol; 2011 Apr; 46(4):385-92. PubMed ID: 20967843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis.
    Westhölter D; Beckert H; Straßburg S; Welsner M; Sutharsan S; Taube C; Reuter S
    J Cyst Fibros; 2021 Nov; 20(6):1072-1079. PubMed ID: 34030985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pro-resolving lipid mediator Resolvin D1 serves as a marker of lung disease in cystic fibrosis.
    Eickmeier O; Fussbroich D; Mueller K; Serve F; Smaczny C; Zielen S; Schubert R
    PLoS One; 2017; 12(2):e0171249. PubMed ID: 28158236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma TGF-β₁ in pediatric cystic fibrosis: potential biomarker of lung disease and response to therapy.
    Harris WT; Muhlebach MS; Oster RA; Knowles MR; Clancy JP; Noah TL
    Pediatr Pulmonol; 2011 Jul; 46(7):688-95. PubMed ID: 21337732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum metabolomics indicate altered cellular energy metabolism in children with cystic fibrosis.
    Joseloff E; Sha W; Bell SC; Wetmore DR; Lawton KA; Milburn MV; Ryals JA; Guo L; Muhlebach MS
    Pediatr Pulmonol; 2014 May; 49(5):463-72. PubMed ID: 23847148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
    Harris JK; Wagner BD; Zemanick ET; Robertson CE; Stevens MJ; Heltshe SL; Rowe SM; Sagel SD
    Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026
    [No Abstract]   [Full Text] [Related]  

  • 29. Interactions between secondhand smoke and genes that affect cystic fibrosis lung disease.
    Collaco JM; Vanscoy L; Bremer L; McDougal K; Blackman SM; Bowers A; Naughton K; Jennings J; Ellen J; Cutting GR
    JAMA; 2008 Jan; 299(4):417-24. PubMed ID: 18230779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling cystic fibrosis disease progression in patients with the rare CFTR mutation P67L.
    MacKenzie IER; Paquette V; Gosse F; George S; Chappe F; Chappe V
    J Cyst Fibros; 2017 May; 16(3):335-341. PubMed ID: 28392015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased Soluble VCAM-1 and Normal P-Selectin in Cystic Fibrosis: a Cross-Sectional Study.
    Nowak JK; Wojsyk-Banaszak I; Mądry E; Wykrętowicz A; Krzyżanowska P; Drzymała-Czyż S; Nowicka A; Pogorzelski A; Sapiejka E; Skorupa W; Szczepanik M; Lisowska A; Walkowiak J
    Lung; 2017 Aug; 195(4):445-453. PubMed ID: 28646244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum zinc concentration in cystic fibrosis patients with CFTR I1234V mutation associated with pancreatic sufficiency.
    AbdulWahab A; Abushahin A; Allangawi M; Chandra P; Abdel Rahman MO; Soliman A
    Clin Respir J; 2017 May; 11(3):305-310. PubMed ID: 26096753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries.
    Volkova N; Moy K; Evans J; Campbell D; Tian S; Simard C; Higgins M; Konstan MW; Sawicki GS; Elbert A; Charman SC; Marshall BC; Bilton D
    J Cyst Fibros; 2020 Jan; 19(1):68-79. PubMed ID: 31196670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Classic respiratory disease but atypical diagnostic testing distinguishes adult presentation of cystic fibrosis.
    Keating CL; Liu X; Dimango EA
    Chest; 2010 May; 137(5):1157-63. PubMed ID: 19965956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data.
    Keogh RH; Szczesniak R; Taylor-Robinson D; Bilton D
    J Cyst Fibros; 2018 Mar; 17(2):218-227. PubMed ID: 29311001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mannose-binding lectin gene as a modifier of the cystic fibrosis phenotype in Argentinean pediatric patients.
    Gravina LP; Crespo C; Giugno H; Sen L; Chertkoff L; Mangano A; Castaños C
    J Cyst Fibros; 2015 Jan; 14(1):78-83. PubMed ID: 25178872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of the cystic fibrosis transmembrane conductance regulator on expression of lipid metabolism-related genes in dendritic cells.
    Xu Y; Tertilt C; Krause A; Quadri LE; Crystal RG; Worgall S
    Respir Res; 2009 Apr; 10(1):26. PubMed ID: 19344509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Airway Mucosal Host Defense Is Key to Genomic Regulation of Cystic Fibrosis Lung Disease Severity.
    Polineni D; Dang H; Gallins PJ; Jones LC; Pace RG; Stonebraker JR; Commander LA; Krenicky JE; Zhou YH; Corvol H; Cutting GR; Drumm ML; Strug LJ; Boyle MP; Durie PR; Chmiel JF; Zou F; Wright FA; O'Neal WK; Knowles MR
    Am J Respir Crit Care Med; 2018 Jan; 197(1):79-93. PubMed ID: 28853905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
    Rowe SM; Heltshe SL; Gonska T; Donaldson SH; Borowitz D; Gelfond D; Sagel SD; Khan U; Mayer-Hamblett N; Van Dalfsen JM; Joseloff E; Ramsey BW;
    Am J Respir Crit Care Med; 2014 Jul; 190(2):175-84. PubMed ID: 24927234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D.
    Hoppe JE; Wagner BD; Kirk Harris J; Rowe SM; Heltshe SL; DeBoer EM; Sagel SD
    J Cyst Fibros; 2022 Nov; 21(6):950-958. PubMed ID: 35440409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.